Evaluating The Effect Of Coenzyme Q10 Augmentation On Treatment Of Bipolar Depression: A Double-Blind Controlled Clinical Trial
Notes for this study:
||MADRS. Mean and SD, Placebo: before 21.64 (6.60), after 14.55 (4.75). Intervention: before 23.92 (5.15), after 11.08 (3.05).
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 89 participants with bipolar disorder undergoing a depressive episode were allocated to take 200 mg/d of coq10 or placebo daily in addition to their usual medication for 8 weeks.
69 participants completed the trial. The primary outcome was depression score on the MADRS, and there was a greater reduction in the coq10 group that was statistically significant compared with placebo.